Journal of Cardiology & Cardiovascular Surgery scientific, open-access, double-blind peer-reviewed journal covering a wide spectrum of topics in cardiology and cardiovascular surgery. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Investigation of serum copeptin levels in patients with congestive heart failure
Aims: Congestive heart failure (CHF) is characterized by symptoms and signs of volume overload and tissue perfusion insufficiency and accompanied by neurohormonal activation. Copeptin is a part of pre-pro-vasopressin and synthesized in equal molar amounts with vasopressin. We aimed to evaluate the sensitivity and specificity of copeptin in indicating the diagnostic value of CHF
Methods: This retrospective study included a total of 80 patients including 40 with heart failure and 40 healthy individuals. The groups were compared in terms of demographic features, laboratory findings including copeptin levels.
Results: There was no statistically significant difference between the groups in terms of gender (p>0.05). Age, hypertension, diabetes mellitus, smoking were statistically significantly higher in the heart failure group compared to the control group (p<0.05). In both groups, serum copeptin levels were higher in men than in women. Copeptin levels in the heart failure group were statistically significantly higher than in the control group (p<0.05). In the heart failure group, there was a negative correlation between serum copeptin levels and age, gender, hypertension, smoking, HDL cholesterol, hematocrit, creatinine levels.
Conclusion: Copeptin is a good indicator of the course of the disease in patients with heart failure.

1. Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heartfailure. ESC Heart Fail. 2019;6:1105-1127.
2. Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heartfailure: a contemporary look at physiology, diagnosis and treatment.Nat Rev Cardiol. 2020;17:641-655.
3. Holwerda DA. Aglycopeptide from the posterior lobe of pig pituitaries:isolation and characterization. Eur J Biochem. 1972;28:334-339.
4. Jochberger ST, Morgenthaler NG, Mayr VD. Copeptin and argininevasopressin cooncentrations in critically ill patients. J Clin EndocrinolMetab. 2006;91:4381-4386.
5. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS.Global burden of heart failure: a comprehensive and updated review ofepidemiology. Cardiovasc Res. 2023;118:3272-3287.
6. Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23505 Medicare patiets hospitalizad with heart failure in Northeast Ohio,1991-1997, Am Heart J. 2003;146:258-264.
7. ACC/AHA Guidelines for the evaluation and management of chronicheart the adult. J Am Coll Cardiol. 2008;38:2101-2113.
8. Kalra PR, Anker STD, Coats JS. Water and sodium regulation inchronic heart failure: the role of natri&uuml;retic peptides and vasopressin.Cardiovasc Res. 2001;51:495-509
9. Chatterjee K. Neurohormonal activation in congestive heart failure andthe role vasoprresin. Am J Cardiol. 2005;95:8-13.
10. Francis GS, Benedict C, Johnstone DE. Compparison of neuroendocrineactivation in patients with left ventriculer dysfunction with and withoutcongestive heart failure: a substudy of the Studies of Left VentricularDysfunction (SOLVD). Circulation 1990;82:1724-1729.
11. Nakamura T, Funayama H, Yoshimura A. Possible vasculer role ofincreased plasma arginine vasopressin in congestive heart failure. Int JCardiol. 2006;106:191-195.
12. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptidederived from the vasopreein precursor, is elevated in serum of sepsispatients. Peptides 2005; 26: 2500-2504.
13. M&uuml;ler B, Morgenthaler N, Stolz D. Circulating levels of copeptin, anovel biomarker, in lower respiratory tract infections. Eur J Clin Invest.2007;37:145-152.
14. Khan SQ, Dhillon OS, O&rsquo;Brien RJ. C-terminal provasopressin(copeptin) as a novel and prognostic marker in acute myokardialinfarction: leicester acute myokardial infarction peptide (LAMP) study.Circulation. 2007;115:21032110.
15. Kannel WB, Ho K, Thom T. Changing epidemiological featuresaetiology of cardiac failure. Br Heart J. 1994;72:53-59.
16. Rouleau J, Packer M, Moye L, de Champlain J, Bichet D, Klein M.Prognostic value of neurohumoral activation in patients with anacute myocardial infarction: effect of captopril. J Am Coll Cardiol.1994;24:583-591.
17. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin(copeptin) is a strong prognostic marker in patients with heart failureafter an acute myocardial infarction: results from the OPTIMAALstudy. Eur Heart J. 2009;30:1187-1194.
18. Masson S, Latini R, Carbonieri E, et al; GISSI-HF Investigators. Thepredictive value of stable precursor fragments of vasoactive peptides inpatients with chronic heart failure: data from the GISSI-heart failure(GISSI-HF) trial. Eur J Heart Fail 2010; 12: 338-347.
19. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin(copeptin) is associated with left ventricular dysfunction, remodeling,and clinical heart failure in survivors of myocardial infarction.JCardiac Fail.2008,14(9):739-745.
20. Neuhold S, Huelsmann M, Strunk G, , et al. J Am Coll Cardiol 2008;52:266-272.
21. Schill F, Timpka S, Nilsson PM, Melander O, Enh&ouml;rning S. Copeptinas a predictive marker of incident heart failure. ESC Heart Fail.2021;8:3180-3188.
22. Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure:Review and meta-analysis. Clin Chim Acta. 2017;475:36-43.
23. Karki KB, Towbin JA, Shah SH, et al. Elevated Copeptin Levels AreAssociated with Heart Failure Severity and Adverse Outcomes inChildren with Cardiomyopathy. Children (Basel). 2023;10:1138.
Volume 2, Issue 2, 2024
Page : 27-30